Aptorum Group Limited (NASDAQ:APM) Sees Large Growth in Short Interest

Aptorum Group Limited (NASDAQ:APM) saw a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 4,600 shares, a growth of 70.4% from the October 15th total of 2,700 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily volume of 19,700 shares, the short-interest ratio is currently 0.2 days.

Aptorum Group Price Performance

APM stock traded down $0.42 during mid-day trading on Friday, hitting $0.68. The stock had a trading volume of 214,931 shares, compared to its average volume of 703,346. Aptorum Group has a 52 week low of $0.64 and a 52 week high of $17.49. The firm has a fifty day simple moving average of $1.85 and a 200 day simple moving average of $3.28.

Institutional Investors Weigh In On Aptorum Group

An institutional investor recently bought a new position in Aptorum Group stock. Murchinson Ltd. acquired a new stake in Aptorum Group Limited (NASDAQ:APM) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 14,000 shares of the company’s stock, valued at approximately $133,000. Murchinson Ltd. owned approximately 0.27% of Aptorum Group as of its most recent SEC filing. 3.80% of the stock is currently owned by institutional investors and hedge funds.

Aptorum Group Company Profile

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.